Ada Girnita

TL;DR: It is reported that certain cyclolignans are potent and selective inhibitors of tyrosine phosphorylation of the IGF-1R, and the possibility to use PPP or related compounds with inhibitory effects on IGF- 1R as lead compounds in development of anticancer agents is opened.

TL;DR: The insulin-like growth factor (IGF-1) signalling is highly implicated in cancer and a close interplay with the p53/MDM2 pathway may cause IGF-1R upregulation and growth advantage for the cancer cell.

TL;DR: It is shown that inhibition of p53 causes ubiquitination and down-regulation, through increased degradation, of the IGF-1R in human malignant melanoma cells, and evidence is provided that Mdm2 serves as a ligase in ubiquitinations of the insulin-like growth factor 1 receptor and thereby causes its degradation by the proteasome system.

TL;DR: The data suggest that the preferential inhibition of phosphorylated Akt, after PPP treatment, may be due to specific inhibition of Y1136, and PPP was proven not to interfere directly with Akt or any of its downstream molecules in the apoptotic pathway.

TL;DR: Evidence is provided that β-arrestin, otherwise known to be involved in the regulation of G protein-coupled receptors, serves as an adaptor to bring the oncoprotein E3 ubiquitin ligase MDM2 to the IGF-1R, which acts as a crucial component in the ubiquitination and down-regulation of the receptor.